Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Incyte Corp (NQ: INCY ) 75.75 -0.38 (-0.50%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Incyte Corp < Previous 1 2 3 4 5 6 Next > Incyte to Present at Upcoming Investor Conferences October 30, 2024 From Incyte Via Business Wire Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs October 29, 2024 From Incyte Via Business Wire Incyte Named One of Top 5 Companies on Science Magazine’s 2024 Top Employers List October 24, 2024 From Incyte Via Business Wire Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program October 10, 2024 From Incyte Via Business Wire Incyte to Report Third Quarter Financial Results October 08, 2024 From Incyte Via Business Wire Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 07, 2024 From Incyte Via Business Wire Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) October 03, 2024 From Incyte Via Business Wire Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress September 25, 2024 From Incyte Via Business Wire Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer September 14, 2024 From Incyte Via Business Wire Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium September 14, 2024 From Incyte Via Business Wire Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 09, 2024 From Incyte Via Business Wire Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024 August 21, 2024 From Incyte Via Business Wire Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma August 15, 2024 From Incyte Via Business Wire Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD) August 14, 2024 From Incyte and Syndax Pharmaceuticals Via Business Wire Incyte to Present at Upcoming Investor Conferences August 13, 2024 From Incyte Via Business Wire Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 07, 2024 From Incyte Via Business Wire Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs July 30, 2024 From Incyte Via Business Wire Incyte to Report Second Quarter Financial Results July 09, 2024 From Incyte Via Business Wire Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 08, 2024 From Incyte Via Business Wire Incyte Announces Final Results of Tender Offer June 13, 2024 From Incyte Corporation Via Business Wire Incyte Announces Preliminary Results of Tender Offer June 11, 2024 From Incyte Corporation Via Business Wire Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 07, 2024 From Incyte Via Business Wire Incyte Completes Acquisition of Escient Pharmaceuticals May 30, 2024 From Incyte Via Business Wire Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings May 21, 2024 From Incyte Via Business Wire Incyte to Present at Upcoming Investor Conference May 21, 2024 From Incyte Via Business Wire Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress May 14, 2024 From Incyte Via Business Wire Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock May 13, 2024 From Incyte Corporation Via Business Wire Incyte to Present at Upcoming Investor Conference May 02, 2024 From Incyte Via Business Wire Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs April 30, 2024 From Incyte Via Business Wire Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists April 23, 2024 From Incyte and Escient Pharmaceuticals Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
